Schumacher K, Maerker-Alzer G, Kleinau T, Hügel W, Dalichau H, Dienst C, Mitrenga D
Dtsch Med Wochenschr. 1982 Oct 1;107(39):1459-64. doi: 10.1055/s-2008-1070148.
In the course of a randomised prospective study involving 98 patients who had undergone cardiac surgery, 51 patients were given 20 g human immunoglobulin i.v. over four months, 47 received merely blood transfusions, like all other patients, averaging 4.4 units per patient. Antibodies against HBs antigen or Hbc antigen were present in 20% of patients before operation. After operation (plus blood transfusions) antibodies against hepatitis-B virus were demonstrated in 43% of the control group but 94% of those treated with immunoglobulins. These antibodies persisted in the course of further immunoglobulin administrations, while they fell in the control group. Hepatitis-B infections occurred in ten patients of the control group, after 30-90 days; three of them developed acute hepatitis. In the group treated with immunoglobulins there were only two patients with an infection, one of whom developed hepatitis. Antibodies against cytomegalic virus increased in the control group but not in the treatment group. In both groups there was the same incidence of non-A-non-B hepatitis.
在一项涉及98例接受心脏手术患者的随机前瞻性研究过程中,51例患者在四个月内静脉注射20克人免疫球蛋白,47例患者仅像所有其他患者一样接受输血,平均每位患者输血4.4单位。术前20%的患者存在抗HBs抗原或抗Hbc抗原抗体。术后(加输血),对照组43%的患者检测出抗乙型肝炎病毒抗体,而接受免疫球蛋白治疗的患者中这一比例为94%。在进一步给予免疫球蛋白的过程中,这些抗体持续存在,而在对照组中抗体水平下降。对照组有10例患者在30 - 90天后发生乙型肝炎感染,其中3例发展为急性肝炎。在接受免疫球蛋白治疗的组中,只有2例患者发生感染,其中1例发展为肝炎。对照组中抗巨细胞病毒抗体增加,而治疗组未增加。两组中非甲非乙型肝炎的发病率相同。